Circulating tumour DNA as a decision-making tool: tumour-informed versus tissue-free assays, minimal residual disease after surgery, and whether a molecular relapse signal should change what treatment a patient receives.
In a prognostic analysis nested within the phase 2 c-TRAK TN trial, a tissue-free ctDNA assay detected molecular residual disease in 54 of 159 patients (34.0%) with early triple negative breast cancer, and detection was strongly associated with recurrence risk (HR, 27.2).
Retrospective subset analysis of the CIRCULATE-Japan GALAXY registry (298 patients with resected colorectal liver metastases) testing whether ctDNA-defined molecular residual disease (MRD) status can identify who actually benefits from adjuvant chemotherapy (ACT) after liver resection